Chronic Lymphocytic Leukemia (CLL), Cutaneous T-cell Lymphoma (CTCL), DLBCL, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Peripheral T-cell Lymphoma (PTCL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia
Conditions
Brief summary
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.
Interventions
DRUGL-Bcl-2 antisense oligonucleotide
There will be 2 planned dose levels, 20, and 40 mg/m\^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.
Sponsors
Bio-Path Holdings, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults ≥18 years of age 2. Patient has a life expectancy ≥ 3 month 3. Patient has relapsed or refractory disease Relapsed lymphoma: Relapsed lymphoma is disease that has responded to treatment but then returns. Refractory lymphoma: Failure to achieve complete response at the end of therapy or progression within 6 months from completion of therapy 4. Included Diseases * DLBCL, including transformed lymphoma * Mantle Cell Lymphoma * PTCL * CTCL * CLL/SLL * Follicular lymphoma * Marginal zone lymphoma * Hodgkin lymphoma (both classical and lymphocyte predominant) * Waldenströms Macroglobulinemia 5. Must has failed or is not a candidate for available therapies with reasonable likelihood of clinical benefit, which includes FDA approved products and standard of care regimens 6. Therapy means at least three front lines of therapy including Hematopoeitic Stem Cell Transplant (HSCT and/or Chimeric Antigen Receptor (CAR) T cells, when applicable 7. Females must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study 8. Males must agree to use an adequate method of contraception during the study 9. Eastern Cooperative Oncology Group (ECOG) Performance score of 0, 1, or 2 10. Adequate hepatic and renal functions as defined by: * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN); and * Total bilirubin ≤1.5 times ULN; and * Estimated glomerular filtration rate (eGFR) of at least 50ml/min. These estimations can be calculated using the following methods: * Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation * Cockcroft Gault equation * Modification of Diet in Renal Disease (MDRD study equation) * Creatinine clearance estimated by 24-hr urine collection for creatinine clearance 11. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment 12. Willing and able to provide written informed consent
Exclusion criteria
1. Active non-hematologic malignancy other than lymphoid malignancies treated with immuno- or chemotherapy within the previous 12 months except active non-melanoma, non-invasive skin cancer will be allowed 2. Known, active Central Nervous System (CNS) involvement of disease requiring intrathecal therapy. Note: Patients with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening 3. Patient eligible for high dose chemotherapy and autologous stem cell transplant 4. Indolent non-Hodgkin lymphoma (iNHL) 5. Patients at high risk of Tumor Lysis Syndrome (TLS) a. Bulky disease i. A unidimensional lesion greater than 10 cm and/or b. Lymphocyte count greater than 25,000 per µL 6. Receipt of any anti-cancer therapy within 14 days prior to Cycle 1 Day 1 (C1D1) 7. Uncontrolled active, untreated, or progressive infection 8. Receipt of any investigational agent or on study treatment within 30 days prior to C1D1 9. Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug 10. Serious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study 11. Active hepatitis B infection (based on positive surface antigen \[HBsAg\]), hepatitis C infection (based on Hepatitis C Virus (HCV) positive antibody \[HCV Ab\]), or human immunodeficiency virus (HIV-1 or HIV-2, based on positive antibody) 12. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant baseline EKG abnormality (e.g., QTcF \>470 msec) 13. Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack 14. Uncontrolled seizure disorder 15. Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine pharmacokinetics (PK) of BP1002 | 30 days | 12-lead EKG assessments will be collected and analyzed for conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) from those the EKG obtained immediately before the first BP1002 dose, and after BP1002 dose, and will mirror the time points used to collect the plasma PK assessments |
| Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002 | 30 days | Identify TEAE of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria |
| Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002 by identification and grading of | 30 days | Identify and grade treatment-emergent laboratory abnormalities of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria |
| Identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) of escalating doses of BP1002 | 30 days | Collection of 12-lead EKGs at defined intervals to identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) |
| Recommended Phase 2 dose (RP2D) of BP1002 | 210 days | Determine RP2D by evaluating Maximally Tolerated Dose (MTD) data: Any Dose Limiting Toxicity (DLT) observed will trigger an expansion of a cohort from 3 to 6 patients. A second DLT at any dose level will identify the Maximum Dose. The dose below that will be the MTD. |
| Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration | 30 days | Evaluate in vivo PK of BP1002 using maximum plasma drug concentration (Cmax) |
| Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution | 30 days | Evaluate in vivo PK of BP1002 volume of distribution (Vd) |
| Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant | 30 days | Evaluate in vivo PK of BP1002 elimination rate constant |
| Determine half-life plasma pharmacokinetics (PK) of BP1002 | 30 days | Evaluate in vivo PK of BP1002 half-life (t1/2) |
| Identify Dose Limiting Toxicity (DLT) of BP1002 | 30 days | Identify DLT of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Activity of BP1002 on Bcl-2 expression in tumor samples | 30 days | Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression using patient blood samples |
| Determine evidence of tumor response by bone marrow aspirate | 30 days | Assess tumor response by evaluating bone marrow aspirate to determine complete response (CR), partial response (PR), or minor response (MR) using appropriate uniform response criteria as published by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th) |
| Determine evidence of tumor response by Complete Blood Count (CBC) | 30 days | Assess tumor response by evaluating CBC measurements to determine complete response (CR), partial response (PR), or minor response (MR) using appropriate uniform response criteria as published by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th) |
| Determine estimates for time to progression (TTP) | 30 days | Measured from treatment start date to date of progression by CBC and/or bone marrow aspirate |
| Determine estimates for progression-free survival (PFS) | 30 days | Measured from treatment start date to date of progression or death by CBC and/or bone marrow aspirate |
| Determine estimates for event-free survival (EFS) | 30 days | Measured from treatment start date to date of progression, death, or change in therapy by CBC and/or bone marrow aspirate |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory objective to correlate treatment response with cytogenetic characteristics | 30 days | Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression |
| Exploratory objective to correlate treatment response with molecular characteristics | 30 days | Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression |
Countries
United States
Outcome results
None listed